Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?

[1] Wu AH(2007)Management of patients with non-ischaemic cardiomyopathy Heart 93 403-408

[2] Cerrato E(2013)Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era Eur Heart J 34 1432-1436

[3] D'Ascenzo F(1997)Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy J Am Coll Cardiol 30 1002-1008

[4] Biondi-Zoccai G(2013)2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 128 1810-1852

[5] Calcagno A(1984)Segmental wall motion abnormalities in dilated cardiomyopathy: a common finding and good prognostic sign J Am Coll Cardiol 4 674-679

[6] Frea S(2011)Cardiovascular magnetic resonance in heart failure Curr Cardiol Rep 13 210-219

[7] Grosso Marra W(2011)Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology Circulation 124 1351-1360

[8] Bart BA(2003)Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance Circulation 108 54-59

[9] Shaw LK(2011)Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance study J Cardiovasc Magn Reson 13 53-1453

[10] McCants CB(2000)The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 1445-1541

[1] Wu AH(2007)Management of patients with non-ischaemic cardiomyopathy Heart 93 403-408

[2] Cerrato E(2013)Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era Eur Heart J 34 1432-1436

[3] D'Ascenzo F(1997)Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy J Am Coll Cardiol 30 1002-1008

[4] Biondi-Zoccai G(2013)2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 128 1810-1852

[5] Calcagno A(1984)Segmental wall motion abnormalities in dilated cardiomyopathy: a common finding and good prognostic sign J Am Coll Cardiol 4 674-679

[6] Frea S(2011)Cardiovascular magnetic resonance in heart failure Curr Cardiol Rep 13 210-219

[7] Grosso Marra W(2011)Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology Circulation 124 1351-1360

[8] Bart BA(2003)Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance Circulation 108 54-59

[9] Shaw LK(2011)Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance study J Cardiovasc Magn Reson 13 53-1453

[10] McCants CB(2000)The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 1445-1541